Sustainability

ESG Performance Data

Applicable range Miraca Holdings Inc., SRL, Inc., Fujirebio Holdings, Inc.
Period From April 1, 2018 to March 31, 2019 (Except where noted)

Environmental

Management
2015 2016 2017 2018
Group companies with ISO 14001 certification 2 2 2 2
Group companies performing environmental audit (internal audit) 2 2 2 3
Group companies performing environmental audit (external audit)*1 2 2 2 3
Group companies performing environmental audit (audit by Miraca Group)*2 23 20 19 17
Employees receiving environmental training*3 5,727*4 5,692 6,030 6,069
Violations of environmental laws or regulations 0 0 0 0
  1. Both internal and external audits performed at SRL and Fujirebio (ALSI)
  2. Audit of waste disposal contractors and environmental measurement contractors of Fujirebio
  3. Total number of employees receiving group-wide environmental training
  4. For SRL, average from April to December
Climate change
Unit 2015 2016 2017 2018
GHG emissions*1 Scope 1 t 9,453 9,141 8,477 7,954
Scope 2 t 23,464 22,217 21,275 19,329
Scope 3 Purchased goods and services t 106,654 101,624 118,139 134,668
Transportation and delivery
(upstream)
t 106,654 101,624 118,139 134,668
Waste generated in operations t 3,255 3,519 3,435 3,447
Business travel t 747 740 784 789
Employee commuting
(including commuting by car)
t 1,120 1,063 1,340 1,319
Transportation and delivery
(downstream)*2
t 45,368 42,755 44,490 40,396
Use of sold products*2 t 2,929 2,810 2,598 2,676
Leased assets (downstream) t 5,565 4,317 5,306 5,219
Total t 272,290 258,451 294,232 323,181
CO2 emissions Scope 1+2 t-CO2 32,917 31,364 29,752 27,283
CO2 emission intensity Scope 1+2 t-CO2 / ¥100 million
(sales)
26.0 25.0 24.0 21.5
NOx emissions*3 t
SOx emissions*3 t
VOC emissions*3 t
Emissions of ozone-depleting substances (ODS)*4
Energy intensity (converted to crude oil) kL / ¥100 million
(sales)
12.1 12.2 12.0 11.0
Energy intensity (products)*3
Consumption rate by energy type*5 Renewables
(converted to crude oil or calories)
% 0 0 0 0
Fuel % 26 26 25 25
Electricity % 74 74 75 75
Carbon offset*3
Energy Use*5 Electricity kL
(converted to crude oil)
11,282 11,246 11,057 10,475
City gas kL
(converted to crude oil)
1,613 2,070 1,961 1,808
LPG (propane gas) kL
(converted to crude oil)
456 1 1 1
Gasoline kL
(converted to crude oil)
1,781 1,704 1,593 1,515
Kerosene kL
(converted to crude oil)
177 209 186 165
Fuel oil kL
(converted to crude oil)
21 17 14 13
Renewable energy 0 0 0 0
Total 15,330 15,248 14,812 13,978
Energy reduction*3
Eco-drive vehicle fuel consumption Refuel L 1,961,961 1,842,073 1,770,508 1,696,934
Distance traveled km 30,970,389 29,864,552 29,278,656 28,615,448
Fuel efficiency L / km 15.8 16.2 16.5 16.9
Year-on-year improvement % 3.0 2.6 2.0 1.9
CDP climate change score*3
  1. Based on Japan’s Ministry of the Environment’s emission source unit database (ver. 2.5) for calculating green gas emissions through the supply chain (March 2018)
  2. For Fujirebio only
  3. Data currently unavailable
  4. Not used
  5. Calculated as a crude oil conversion value
Waste
Units 2015 2016 2017 2018
Waste output per sales*1 t / ¥100 million 1.8 1.8 2.0 2.0
Amount of waste generated t 2,288 2,307 2,537 2,582
Breakdown of waste generated General waste t 473 366 264 239
Industrial waste t 1,070 1,127 1,492 1,502
Specially controlled industrial waste t 745 814 781 840
Recycling rate*2 % 97 90.7 85 85
Emissions of PRTR Law Class I Designated Chemical Substances*2 t 3.6 4.2 3.9 3.0
  1. Divided by sales amount
  2. Total for Fujirebio only
Water
Units 2015 2016 2017 2018
Water used Thousand m3 229 223 217 209
Waste water Thousand m3 219 213 208 202
Waste water per sales*1 Thousand m3 / ¥100 million
(sales)
0.17 0.17 0.17 0.16
COD (chemical oxygen demand)*2 t 0.2 0.3 0.4 0.4
  1. Divided by sales amount
  2. Total for Fujirebio only

Social

Customers
2015 2016 2017 2018
Rate of participation in control survey and quality control reporting at medical institutions using the LUMIPULSE system 91% 89% 85% 90%
Number of voluntarily recall incidents In Vitro Diagnostics business*1 0 1 0 0
Number of serious nonconformities In Vitro Diagnostics business*1 0 1 0 0
Clinical Laboratory Testing business*2 1 1 1 1
  1. Voluntary recall incidents defined as serious nonconformities
  2. Cases requiring administrative response
Business partners
2015 2016 2017 2018
Number of suppliers 485 498 592 595
Percentage of suppliers performing risk assessment*1
Reported cases of child labor at suppliers 0 0 0 0
Reported cases of forced labor at suppliers 0 0 0 0
  1. Data currently unavailable
Employees
2015 2016 2017 2018
Number of employees Regular employees (female)*1 1,034 1,039 1,245 1,260
Regular employees (male)*1 1,618 1,562 1,844 1,975
Managers (female)*1, 2 23 21 50 66
Managers (male)*1, 2 237 215 334 401
Directors and Officers*3 12 12 13 12
Number of employees by area*1 Japan (female) 1,056 1,059 1,294 1,326
Japan (male) 1,846 1,766 2,169 1,966
Asia (female) 1 1 1 1
Asia (male) 6 6 4 5
North America (female) 0 0 0 0
North America (male) 3 3 4 1
Europe (female) 0 0 0 0
Europe (male) 0 2 1 1
Average age*4 43.9 44.6 42.9 42.5
Number of women employees in new hires*1 Male 10 21 25 59
Female 16 32 34 99
Average employment year*4 Male 14.2 14.3
Female 10.6 11.1
Percentage difference 3.6 3.26
Annual working hours per employee*4 2,054 2,001 2,015 2,034
Average days of paid leave taken*4 8 8 7 7.5
Average rate of paid leave taken*4 42.5% 44.5% 43.4% 44.0%
Work-related deaths*1 0 0 0 0
Lost time injury frequency rate*1 0.55% 1.10% 0.79% 6.7%
Percentage of female managers*1, 2 9.4% 10.0% 11.8% 14.1%
Percentage of female new recruits incl. mid-career employment*1 48.4% 40.5% 43.4% 49.1%
Average years of employment (years / employee)*4 16.7 17.2 16.5 13.0
Under age 30 2.5 2.7 2.7 1.6
Age 30 to 50 14.6 14.9 15.0 10.7
Age 50 and over 24.4 24.5 24.7 23.2
Employees with disabilities*1 75 77 67 66
Percentage of employees with disabilities*1 2.20% 2.20% 2.01% 1.97%
Foreign-national employees*4 10 10 14 16
Employees taking parental leave (including paternity leave)*4 43 66 66 84
Percentage of employees taking parental leave (including paternity leave)*4 95.3% 98.1% 98.1% 100.0%
Percentage of employees returning to work after maternity / parental leave*4 97.2% 100% 100% 90.6%
Employees taking family care leave (short term)*4 10 36 24 21
Employees taking family care leave (long term)*4 1 2 3 3
Average annual salary of employees*4 7,679,456 7,307,152 7,387,697 6,791,909
Employee turnover rate*4 5.3% 5.7% 6.2% 5.0%
Percentage of employees undergoing medical checkup*4 94.27% 94.42% 92.72% 94.90%
Average annual training time per employee 11
Employees passing DMR qualification exam*1 5 1 7 28
Participants in human error prevention courses*1 35 32 44 41
Average monthly overtime hours*4 19.5 17.8 21.5 19.0
  1. For the 3 companies
  2. Managers & above
  3. For Miraca Holdings, Inc.
  4. Full-time employees of the 3 companies
Community
2015 2016 2017 2018
Participants in philanthropic activities*1 300 300 300 1,514
Participants in Miraca Group Summer Festival Over 2,000 Over 2,000 Over 2,000 Over 2,000
Charitable trust fund*2 Research subsidies
(JPY)
209,800,000 214,800,000 219,800,000 224,800,000
Koichiro Fujita Award
(JPY)
6,000,000 6,500,000 7,000,000 7,500,000
Nozomu Kosakai Award
(JPY)
13,000,000 13,500,000 14,000,000 14,500,000
Seminars held in China 12 30 Over 100 Over 100
Marrow donor program (No. of cases) 9,458 8,801 8,363 9,244
  1. Full-scale operation since FY2018. Lower estimate up to FY2017.
  2. Cumulative amount for each category
Shareholders
2015 2016 2017 2018
Shareholder / investor Engagement 292 325 303 219

Governance

Compliance
2015 2016 2017 2018
Violations of anti-corruption policies and procedures 0 0 0 0
Fines for violations stated above 0 0 0 0
Percentage of employees taking compliance comprehension test 97.30% 99% 95.4%
Inquiries to IT Service Desk*1 9,531 18,251
Cases reported to Miraca Group Hotline 36 59 104 109
  1. Established in FY2017